

In the Claims

1-67 (canceled).

68 (new). An isolated polypeptide comprising SEQ ID NO: 14, SEQ ID NO: 16, or a polypeptide having at least 95% identity to SEQ ID NO: 14, SEQ ID NO: 16 and having beta defensin activity.

69 (new). The isolated polypeptide according to claim 68, wherein said polypeptide comprises SEQ ID NO: 14.

70 (new). The isolated polypeptide according to claim 68, wherein said polypeptide comprises SEQ ID NO: 16.

71 (new). The isolated polypeptide according to claim 68, wherein said polypeptide comprises a polypeptide having at least 95% identity to SEQ ID NO: 14 and has a beta defensin activity.

72 (new). The isolated polypeptide according to claim 68, wherein said polypeptide comprises polypeptide having at least 95% identity to SEQ ID NO: 16 and has a beta defensin activity.

73 (new). A composition comprising a pharmaceutically acceptable excipient and a polypeptide comprising SEQ ID NO: 14, SEQ ID NO: 16, or a polypeptide having at least 95% identity to SEQ ID NO: 14, SEQ ID NO: 16 and having beta defensin activity.

74 (new). The composition according to claim 73, wherein said polypeptide comprises SEQ ID NO: 14.

75 (new). The composition according to claim 73, wherein said polypeptide comprises SEQ ID NO: 16.

76 (new). The composition according to claim 73, wherein said polypeptide comprises a polypeptide having at least 95% identity to SEQ ID NO: 14 and has a beta defensin activity.

77 (new). The composition according to claim 73, wherein said polypeptide comprises a polypeptide having at least 95% identity to SEQ ID NO: 16 and has a beta defensin activity.